Deal Tracker · Countries

Saudi Arabia pharma M&A deals

4 m&a / acquisition deals involving Saudi Arabia tracked by EPT (2026). Most active: Alfasigma, AUG Pharma, Bausch Health & DKSH. Latest: DKSH → NewBridge Pharmaceuticals (M&A / Acquisition, 19 Oct 2026).

4
deals tracked
17
countries involved
$390m
disclosed value (1 deal)
100%
M&A, the top deal type
  • EPT has tracked 4 Saudi Arabia pharma M&A deals (2026).
  • The countries that appear most often are Egypt (3), UAE (3), Algeria (2) & Kuwait (2).
  • Values were disclosed for 1 of 4 deals, totalling $390m; the largest is DKSH → NewBridge Pharmaceuticals ($390m, 19 Oct 2026).

Countries involved

Egypt (3) · UAE (3) · Algeria (2) · Kuwait (2) · Lebanon (2) · Bahrain (1)

Largest disclosed deals

Questions

How many Saudi Arabia pharma M&A deals has EPT tracked?
4 as of 19 Oct 2026, covering 2026. The most recent is DKSH → NewBridge Pharmaceuticals (M&A / Acquisition, 19 Oct 2026).
What is the largest disclosed Saudi Arabia pharma M&A deal?
DKSH → NewBridge Pharmaceuticals: $390m (M&A / Acquisition, 19 Oct 2026). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)